LONDON (Reuters) – Novo Nordisk posted on Thursday first-quarter operating profit above analyst forecasts, as the Danish drugmaker races to boost output of its hugely popular weight-loss drug Wegovy and fend off competition from Eli Lilly.
(Reporting by Maggie Fick; Editing by Terje Solsvik)
Comments